0001680581-17-000001.txt : 20170510 0001680581-17-000001.hdr.sgml : 20170510 20170510100741 ACCESSION NUMBER: 0001680581-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170510 DATE AS OF CHANGE: 20170510 EFFECTIVENESS DATE: 20170510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-286393 FILM NUMBER: 17828828 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 700, SUITE B7102 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 700, SUITE B7102 CITY: CAMBRIDGE STATE: MA ZIP: 02139 D 1 primary_doc.xml X0707 D LIVE 0001680581 Fulcrum Therapeutics, Inc. ONE KENDALL SQUARE BUILDING 700, SUITE B7102 CAMBRIDGE MA MASSACHUSETTS 02139 617-651-8851 DELAWARE None None Corporation true 2015 Robert Gould One Kendall Square Building 700, Suite B7102 Cambridge MA MASSACHUSETTS 02139 Executive Officer Director Mark Levin One Kendall Square Building 700, Suite B7102 Cambridge MA MASSACHUSETTS 02139 Director James Geraghty One Kendall Square Building 700, Suite B7102 Cambridge MA MASSACHUSETTS 02139 Director James Collins One Kendall Square Building 700, Suite B7102 Cambridge MA MASSACHUSETTS 02139 Director Alan Ezekowitz One Kendall Square Building 700, Suite B7102 Cambridge MA MASSACHUSETTS 02139 Director Biotechnology Decline to Disclose 06b false 2017-04-28 false true false 0 5000000 5000000 0 false 1 0 0 0 false Fulcrum Therapeutics, Inc. /s/ Robert Gould Robert Gould President and Chief Executive Officer 2017-05-10